To overcome these roadblocks, we performed scRNA-seq on a genetically engineered EGFR-driven mouse GBM model and flow cytometric analyses of mouse and patient GBM samples to determine their immunological cellular landscape at various stages of disease evolution and during SOC therapies. This evidence concerns the gene EGFR and glioblastoma.